Peginterferon beta-1a - Biogen

Drug Profile

Peginterferon beta-1a - Biogen

Alternative Names: BIIB 017; PEG-interferon-β-1a; PEGylated INF-beta-1a - Biogen; Plegridy

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Interferons; Neuroprotectants
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 23 Oct 2017 Eisai and Biogen agree to co-promote Peginterferon beta-1a in India and other Asia-Pacific countries
  • 28 Apr 2017 Efficacy data from five phase III trials in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 22 Apr 2017 Efficacy data from the phase IIIb ALLOW trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top